Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care

F. Behrens¹, G.-R. Burmester², M. Feuchtenberger³, H. Kellner⁴, C. Kuehne⁵, A. Liebhaber⁶, S. Wassenberg⁷, J. Gerlach⁸, M. Zortel⁸, M.W. Hofmann⁹, C. Amberger¹⁰

¹CIRI/Rheumatology University Hospital and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for Translational Medicine and Pharmacology TMP and Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, Goethe University, Frankfurt;
²Charité-Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin;
³Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen;
⁴Scherpunktpraxis für Rheumatologie und Gastroenterologie, Munich;
⁵Internistisch-Rheumatologische Schwerpunktpraxis, Haldensleben;⁶Internistisch-Rheumatologische Arztpraxis, Halle;⁷Rheumazentrum Ratingen, Ratingen;⁸Roche Pharma AG, Grenzach-Wyhlen;⁹Chugai Pharma Germany GmbH, Rheumatology, Frankfurt am Main;
¹⁰Rheumatologische Gemeinschaftspraxis, Bad Neuenahr, Germany.

Abstract

Objective

To assess whether tocilizumab treatment is associated with changes in depression symptoms in patients with rheumatoid arthritis (RA) during routine daily care.

Methods

We retrospectively analysed data from a German non-interventional study (ARATA) of adult, tocilizumab-naïve RA patients who initiated subcutaneous tocilizumab and were followed for 52 weeks. The Beck Depression Inventory II (BDI-II) was used to assess symptoms of depression and create baseline subgroups of no (BDI-II<14), mild (14–19), moderate (20–28), and severe (≥29) depression. Other key outcomes included Disease Activity Score-28 joints (DAS28), patient-reported outcomes (PROs), and adverse events. Mixed model repeated measures (MMRM) assessed the impact of DAS28 on BDI-II over time, and Pearson correlation analyses evaluated associations between changes from baseline.

Results

Of 474/1155 ARATA patients who completed the BDI-II at baseline, 47.7% had evidence of depression: 18.4% mild, 17.7% moderate, and 11.6% severe. 229 patients (48.3%) completed the BDI-II at both baseline and week 52. Two-thirds of patients with moderate or severe depression at baseline improved to a milder or no depression subgroup at week 52 (44/65 [67.7%]). Improvements in disease activity and PROs were observed in all subgroups, but patients with depression had lower response and higher adverse events rates. We observed an association between DAS28 and BDI-II over time in MMRM analyses, but the Pearson correlation for change from baseline was weak (r=0.10).

Conclusion

Depression is common in patients receiving routine care for RA. Improvements in depressive symptoms in RA during tocilizumab therapy appear to be distinct from changes in disease activity.

Key words
tocilizumab, depression, rheumatoid arthritis, disease activity, biologic agents
Introduction
Symptoms of depression are common in patients with rheumatoid arthritis (RA) (1). In a recent study, more than half of RA patients reported mild or worse depression and 23% reported moderate or worse depression (2). Compared with matched cohorts without RA, RA patients have an approximately 50% higher incidence of depression (3). Despite changes in management, including the widespread use of anti-tumour necrosis factor (TNF) agents and treat-to-target strategies, the risk of depression in patients with RA remained fairly steady between 1989 and 2012 (1). It has been hypothesised that higher rates of depression in RA may be related to the increased inflammatory burden associated with this disease (4).

Interleukin-6 (IL-6) levels are increased in patients with depression (5) and several lines of evidence implicate this cytokine in the pathogenesis of depression (6). In a study involving healthy volunteers, induction of systemic inflammation by endotoxin administration resulted in both depressive symptoms and increased IL-6 in the cerebrospinal fluid. IL-6 levels correlated with dysthymia scores at all time points (7). A meta-analysis of studies of peripheral cytokine levels in major depressive disorder found that treatment with antidepressants significantly reduced IL-6 levels (8).

Tocilizumab, a humanised monoclonal antibody that inhibits the IL-6 signaling pathway by binding to the IL-6 receptor, is approved for the treatment of RA and is used to treat RA patients with active disease throughout the world (9). Small studies (9) and meta-analyses (10) have suggested a decrease in depressive symptoms in RA patients treated with tocilizumab. The aim of the current study was to assess whether tocilizumab was associated with changes in symptoms of depression during routine daily care of patients with RA.

Outcomes
Outcome data encompassed patient-reported mental health, additional patient-reported outcomes (PROs), and measures of disease activity.

Mental health outcomes were assessed by the Beck Depression Inventory II (BDI-II) questionnaire at baseline (BDI-II cohort).

Study design
This was a post-hoc analysis of data from a prospective, multicentre, non-interventional study of German patients with RA (the ARATA study; NCT02251860). Adult (≥18 years) tocilizumab-naive patients with active RA based on clinician assessment who initiated tocilizumab therapy during routine clinical care were eligible for study enrolment. No other inclusion criteria were applied. All patients gave informed consent. The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice Guidelines. Ethics approval was obtained from the Ethics Commission of the Medical Department of Goethe University, Frankfurt am Main, Germany and the Ethics Commission of the Medical Association of Rheinland-Pfalz, Mainz, Germany.

Data collection began at the baseline visit (week 0) before initiation of tocilizumab treatment; the data reported here are based on the first 52 weeks following study initiation (study visits at weeks 4, 12, 24, 36, and 52). Data were collected on an electronic case report form, patient diaries, and questionnaires. The effectiveness set was defined as all eligible patients with documented informed consent who received a first dose of subcutaneous (SC) tocilizumab on or within four weeks after the baseline visit and had at least one post-baseline visit.

By German law, patients had the discretion to choose which self-report questionnaires to complete. The evaluations reported here focus on patients who completed the Beck Depression Inventory II (BDI-II) questionnaire at baseline (BDI-II cohort).
BDI-II scores ≤14 were classified as “no depression,” scores of 14-19 were considered “mild depression,” scores of 20 to 28 “moderate depression,” and ≥29 “severe depression” (12). BDI-II changes of ≥10 to ≤10 were considered no or minimal change, changes >10 were considered moderate to large deterioration, and changes <10 were considered large to moderate improvement (13). Suicidal ideation was assessed by BDI-II question 9; any answer other than no (=0) was considered as “yes.” The study physician was informed by email about outcomes with BDI-II ≥14 or suicidal ideation.

The STAI is a patient-reported questionnaire with two 20-item subscales measuring how respondents feel “right now” (state anxiety; STAI-state) and their overall inclination for anxiety (trait anxiety; STAI-trait). Higher scores indicate greater anxiety (14).

PROs were used to assess global disease activity, pain, fatigue, sleep, and function. The patient global assessment of health (PhGA), pain (last 7 days), fatigue (last 7 days), and sleep difficulties (last 4 weeks) were assessed on 100-point visual analogue scales (VAS) from 0 mm (best possible status) to 100 mm (worst possible status). The Health Assessment Questionnaire-Disability Index (HAQ-DI), a measure of functional ability, was assessed on a scale of 0 (best) to 3 (worst) (15). HAQ-DI ≤0.5 was considered functional remission.

We used the Disease Activity Score based on 28 joints (DAS28) and the Clinical Disease Activity Index (CDAI) as assessments of disease activity; higher scores indicate greater disease activity for both. DAS28 was calculated using erythrocyte sedimentation rate (ESR) as the acute phase reactant (DAS28-ESR). Remission was defined as ≤2.6 (16) and an individual therapeutic response (DAS28-crd) was defined as a DAS28-ESR decrease ≥1.8 from baseline (17). For the CDAI (18), remission was defined as ≤2.8 (16). The physician global assessment of health (PhGA) was assessed by the clinician on a VAS from 0 (best) to 100 (worst) possible status.

Safety analyses were based on adverse event reports obtained at each visit.

### Table I. Baseline characteristics of patients with completed BDI-II questionnaires by BDI-II subgroup.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No depression (BDI-II &lt;14)</th>
<th>Mild depression (BDI-II 14-19)</th>
<th>Moderate depression (BDI-II 20-28)</th>
<th>Severe depression (BDI-II ≥29)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n*</td>
<td>248</td>
<td>87</td>
<td>84</td>
<td>55</td>
</tr>
<tr>
<td>Age, mean (SD)</td>
<td>56.0 (12.7)</td>
<td>55.3 (11.6)</td>
<td>54.6 (12.5)</td>
<td>55.4 (13.5)</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>70.6 (67)</td>
<td>77.0 (69)</td>
<td>82.1 (69)</td>
<td>87.3 (68)</td>
</tr>
<tr>
<td>RA disease duration, mean (SD)</td>
<td>11.2 (8.8)</td>
<td>10.3 (10.4)</td>
<td>9.9 (8.8)</td>
<td>9.8 (9.3)</td>
</tr>
<tr>
<td>Use of antidepressants, n (%)</td>
<td>5 (2.0)</td>
<td>5 (2.6)</td>
<td>11 (13.1)</td>
<td>29 (52.7)</td>
</tr>
<tr>
<td>Use of antitumor necrosis factor inhibitors, n (%)</td>
<td>9 (3.7)</td>
<td>12 (13.8)</td>
<td>18 (21.4)</td>
<td>30 (54.5)</td>
</tr>
<tr>
<td>Pain, mean (SD)</td>
<td>51.6 (27.8)</td>
<td>61.2 (23.6)</td>
<td>62.3 (24.8)</td>
<td>71.6 (21.4)</td>
</tr>
<tr>
<td>Sleep disturbance, mean (SD)</td>
<td>35.0 (30.0)</td>
<td>50.7 (30.6)</td>
<td>59.2 (28.7)</td>
<td>67.2 (28.2)</td>
</tr>
<tr>
<td>Prior therapy, n (%)</td>
<td>sDMARD only</td>
<td>95/248 (38.3)</td>
<td>28/87 (32.2)</td>
<td>30/84 (35.7)</td>
</tr>
<tr>
<td></td>
<td>bDMARD only</td>
<td>74/248 (29.8)</td>
<td>20/87 (23.0)</td>
<td>17/84 (20.2)</td>
</tr>
<tr>
<td></td>
<td>sDMARD and bDMARD</td>
<td>78/248 (31.5)</td>
<td>39/87 (44.8)</td>
<td>36/84 (42.9)</td>
</tr>
<tr>
<td>Therapy at baseline, n (%)</td>
<td>No information</td>
<td>1/248 (0.4)</td>
<td>0</td>
<td>1/84 (1.2)</td>
</tr>
<tr>
<td>SC TCZ therapy</td>
<td>248/248 (100)</td>
<td>87/87 (100)</td>
<td>84/84 (100)</td>
<td>55/55 (100)</td>
</tr>
<tr>
<td>TCZ + any sDMARD</td>
<td>91/248 (36.7)</td>
<td>36/87 (41.4)</td>
<td>22/84 (26.2)</td>
<td>16/55 (29.1)</td>
</tr>
<tr>
<td>TCZ without sDMARD</td>
<td>157/248 (63.3)</td>
<td>51/87 (58.6)</td>
<td>62/84 (73.8)</td>
<td>39/55 (70.9)</td>
</tr>
<tr>
<td>Systemic glucocorticoids</td>
<td>151/248 (60.9)</td>
<td>57/87 (65.5)</td>
<td>58/84 (69.6)</td>
<td>33/55 (60.0)</td>
</tr>
<tr>
<td>Mean glucocorticoid dose in mg/day (SD)</td>
<td>6.1 (3.6)</td>
<td>7.5 (5.1)</td>
<td>7.8 (7.1)</td>
<td>7.1 (3.9)</td>
</tr>
<tr>
<td>STAI-Trait, mean (SD)</td>
<td>36.3 (8.5)</td>
<td>43.9 (8.8)</td>
<td>47.3 (9.0)</td>
<td>57.2 (8.2)</td>
</tr>
<tr>
<td>STAI-State, mean (SD)</td>
<td>11.2 (8.8)</td>
<td>10.3 (10.4)</td>
<td>9.9 (8.8)</td>
<td>9.8 (9.3)</td>
</tr>
<tr>
<td>DAS28-ESR, mean (SD)</td>
<td>4.9 (1.2)</td>
<td>5.0 (1.2)</td>
<td>4.9 (1.3)</td>
<td>4.9 (1.3)</td>
</tr>
<tr>
<td>CDAI, mean (SD)</td>
<td>23.9 (10.2)</td>
<td>25.3 (10.6)</td>
<td>24.7 (10.7)</td>
<td>24.2 (9.2)</td>
</tr>
<tr>
<td>PhGA, mean (SD)</td>
<td>57.3 (21.6)</td>
<td>58.3 (21.6)</td>
<td>58.7 (21.6)</td>
<td>58.5 (21.0)</td>
</tr>
</tbody>
</table>

*If not indicated otherwise, *Evaluated on a visual analogue scale from 0 (best) to 100 (worst) 

†Based on free text entry from patient self-report; antidepressant use was not included on the case report form and past medical records were not evaluated.

BDI-II: Beck Depression Inventory II; CDAI: Clinical Disease Activity Index; DAS28: Disease Activity Score based on 28 joint count; ESR: erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire-Disability Index; PGA: patient global assessment; PhGA: physician global assessment; RA: rheumatoid arthritis; SC: subcutaneous; SD: standard deviation; sDMARD: synthetic disease-modifying antirheumatic drug (methotrexate [oral or parental], leflunomide, cyclosporine A, gold, aza-thioprine, tofacitinib, sulfasalazine); STAI: State-Trait Anxiety Index; TCZ: tocilizumab.

### Statistical analyses

Statistical analyses were performed using SAS v. 9.4 (Cary, NC, USA). Descriptive statistics or frequencies were computed for all data as appropriate. Missing data were not imputed. Analyses on change from baseline to week 52 were performed on patients in the BDI-II cohort with data for the given evaluation at both time points. Pearson correlation analyses with 95% confidence intervals (CIs) were used to ex-
plore association between change from baseline for specified pairs of variables; CIs that crossed zero indicated that no statistically significant correlation was observed. As this was an observational study, CIs should be considered descriptive. Mixed models repeated measures (MRRM) analyses were used to evaluate the association of DAS28-ESR and BDI-II over time, with DAS28-ESR and BDI-II scores as continuous variables and time as visits from baseline to week 52. An unstructured covariance matrix was used. p-values <0.05 were considered significant.

Results
Patient population
Patients were enrolled from 108 clinical centers throughout Germany between 23 May 2014 and 11 July 2018. The effectiveness set encompassed 1155 patients of whom 856 (74.1%) were female. The mean (standard deviation [SD]) age was 57.4 (12.3) years and the mean (SD) RA duration was 10.1 (9.1) years (Supplementary Table S1).

A total of 474 patients (41.0%) in the effectiveness cohort completed the BDI-II questionnaire at baseline (BDI-II cohort; Table I). Of these patients, 256 had BDI-II data at week 24 and 229 had BDI-II data at week 52 (Suppl. Fig. S1). Patients who completed the BDI-II had similar baseline characteristics to patients who did not complete this questionnaire (n=681; Suppl. Table S2), including DAS28-ESR (mean [SD] of 4.9 [1.2]) for patients who completed the BDI-II vs. 4.9 [1.3] for those who did not) and PGA (62.3 [22.4] vs. 64.3 [20.8]).

Almost half (226/474; 47.7%) of the patients in the BDI-II cohort had evidence of depression as indicated by BDI-II scores ≥14. About 30% reported moderate (84; 17.7%) or severe (55; 11.6%) depression. Patients with more severe depression showed differences in baseline characteristics compared with patients with less severe depression (Table I). Disease activity scores were generally comparable across depression subgroups, but patients with severe depression reported reduced functional ability (HAQ-DI) and higher levels of anxiety, fatigue, pain, and sleep disturbance. PGA scores increased with increasing depression, but PhGA scores were similar. Patients with severe depression were more likely to be female than patients with no depression (87.3% vs. 70.6%). A greater proportion of patients with severe depression used antidepressants, and over half (29/55; 52.7%) reported suicidal ideation (Table I).

Statistical analyses of these differences were not considered appropriate due to the influence of confounding factors. Comorbidities were common in the BDI-II patient cohort (Suppl. Table S2).

Depression was identified as a baseline comorbidity based on review of medical records in 35/472 (7.4%) of patients (no comorbidity data were available for 2 patients). Almost half of patients with severe depression reported arterial hypertension (27/55 [49.1%]) compared with 32.5% to 38.1% in subgroups with no or milder depression. Hepatic disease

Table II. Changes in measures of depression and disease activity outcomes over 52 weeks by baseline BDI-II subgroup.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>No depression (BDI-II &lt;14)</th>
<th>Mild depression (BDI-II 14-19)</th>
<th>Moderate depression (BDI-II 20-28)</th>
<th>Severe depression (BDI-II ≥29)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n at baseline</td>
<td>248</td>
<td>87</td>
<td>84</td>
<td>55</td>
</tr>
<tr>
<td>Change from baseline to week 52, mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BDI-II</td>
<td>[125]</td>
<td>[39]</td>
<td>[39]</td>
<td>[26]</td>
</tr>
<tr>
<td>[n evaluated]</td>
<td>[143]</td>
<td>[45]</td>
<td>[43]</td>
<td>[29]</td>
</tr>
<tr>
<td>STAI-State</td>
<td>-2.3 (9.3)</td>
<td>-4.1 (12.4)</td>
<td>-7.0 (12.7)</td>
<td>-4.6 (10.5)</td>
</tr>
<tr>
<td>[n evaluated]</td>
<td>[138]</td>
<td>[46]</td>
<td>[46]</td>
<td>[30]</td>
</tr>
<tr>
<td>STAI-Trait</td>
<td>-1.7 (8.1)</td>
<td>-1.7 (9.2)</td>
<td>-4.3 (10.0)</td>
<td>-7.1 (6.9)</td>
</tr>
<tr>
<td>[n evaluated]</td>
<td>[138]</td>
<td>[47]</td>
<td>[46]</td>
<td>[29]</td>
</tr>
<tr>
<td>CDAI</td>
<td>-160.0 (12.6)</td>
<td>-172.2 (11.4)</td>
<td>-156.0 (14.2)</td>
<td>-12.9 (9.7)</td>
</tr>
<tr>
<td>[n evaluated]</td>
<td>[204]</td>
<td>[64]</td>
<td>[56]</td>
<td>[37]</td>
</tr>
<tr>
<td>HAQ-DI</td>
<td>-0.1 (0.6)</td>
<td>-0.3 (0.5)</td>
<td>-0.4 (0.7)</td>
<td>-0.3 (0.5)</td>
</tr>
<tr>
<td>[n evaluated]</td>
<td>[177]</td>
<td>[61]</td>
<td>[55]</td>
<td>[56]</td>
</tr>
<tr>
<td>PGA</td>
<td>-32.6 (30.8)</td>
<td>-38.1 (25.6)</td>
<td>-34.0 (33.2)</td>
<td>-33.1 (29.0)</td>
</tr>
<tr>
<td>[n evaluated]</td>
<td>[208]</td>
<td>[65]</td>
<td>[59]</td>
<td>[38]</td>
</tr>
<tr>
<td>PhGA</td>
<td>-37.6 (28.6)</td>
<td>-39.3 (26.7)</td>
<td>-36.6 (30.1)</td>
<td>-30.9 (29.7)</td>
</tr>
<tr>
<td>[n evaluated]</td>
<td>[206]</td>
<td>[64]</td>
<td>[61]</td>
<td>[38]</td>
</tr>
<tr>
<td>Fatigue</td>
<td>-8.6 (3.2)</td>
<td>-14.4 (3.5)</td>
<td>-18.1 (3.2)</td>
<td>-18.3 (28.6)</td>
</tr>
<tr>
<td>[n evaluated]</td>
<td>[135]</td>
<td>[47]</td>
<td>[44]</td>
<td>[26]</td>
</tr>
<tr>
<td>Pain</td>
<td>-16.6 (3.5)</td>
<td>-23.9 (26.9)</td>
<td>-26.2 (34.6)</td>
<td>-34.7 (29.5)</td>
</tr>
<tr>
<td>[n evaluated]</td>
<td>[138]</td>
<td>[47]</td>
<td>[43]</td>
<td>[26]</td>
</tr>
<tr>
<td>Sleep disturbance,</td>
<td>-3.7 (3.7)</td>
<td>-11.1 (26.0)</td>
<td>-21.5 (27.3)</td>
<td>-9.7 (26.7)</td>
</tr>
<tr>
<td>[n evaluated]</td>
<td>[136]</td>
<td>[45]</td>
<td>[44]</td>
<td>[26]</td>
</tr>
</tbody>
</table>

Week 52 response and remission rates, n/N (%) (BDI-II <14) 92/138 (66.7) 32/47 (68.1) 27/46 (58.7) 15/29 (51.7) (BDI-II 14-19) 98/153 (64.1) 29/48 (60.4) 30/53 (56.6) 13/29 (44.8) (BDI-II 20-28) 68/207 (32.9) 18/64 (28.1) 19/63 (30.2) 5/58 (13.2) (BDI-II ≥29) 89/211 (42.2) 17/67 (25.4) 21/66 (31.8) 4/39 (10.3) DAS28-ESR-d <crit (decrease ≥1.8) 52/71 (73.2) 5/46 (10.9) 4/46 (8.7) 7/230 (3.0) 27/33 (81.0) 16/71 (22.5) 5/46 (10.9) TCZ therapy 189/230 (82.2) 51/73 (69.9) 52/71 (73.2) 29/46 (63.0) TCZ + any sDMARD 62/230 (27.0) 22/73 (30.1) 16/71 (22.5) 5/46 (10.9) TCZ without sDMARD 127/230 (55.2) 29/73 (39.7) 36/71 (50.7) 24/46 (52.2) Other biologic therapy 22/230 (9.6) 10/73 (13.7) 17/71 (24.6) 5/46 (10.9) systemic glucocorticoids 103/230 (44.8) 34/73 (46.6) 31/71 (43.7) 18/46 (39.1) Mean glucocorticoid dose in mg/day (SD) 5.3 (3.8) 6.0 (4.4) 6.6 (4.9) 5.3 (2.4)
and fibromyalgia were also more common in patients with severe depression.

**Changes in symptoms of depression**

The majority of patients with baseline BDI-II data remained in the study throughout the 52-week period (414/474 [87.3%]) (Suppl. Fig. S1). Of the patients remaining in the BDI-II cohort, 48 (11.6%) had switched to another biological disease-modifying anti-rheumatic drug (DMARD) at week 52, 20 (4.8%) were on a synthetic DMARD alone, and 14 (3.4%) were treated with intravenous (IV) tocilizumab. Compared with patients with no or mild depression, higher proportions of patients with severe depression switched to IV tocilizumab or to a synthetic DMARD alone (Table II).

A total of 229 of the 474 patients (48.3%) in the BDI-II cohort completed the BDI-II at both baseline and week 52. In this subgroup of patients with data at both time points, increases were observed in the proportion of patients with no depression and mild depression, while decreases occurred in the proportions of patients with moderate or severe depression (Fig. 1). Of the 39 patients with moderate depression at baseline, almost three-quarters improved to no depression (18/39 [46.2%]) or mild depression (11/39 [28.2%]) at week 52; moderate depression remained unchanged in 8 patients (20.5%) and worsened to severe depression in 2 (5.1%). The 26 patients with severe depression at baseline were somewhat more resistant to improvements in symptoms, with 11 (42.3%) continuing to report severe depression, but the majority showed improvements in depressive symptoms. Overall, 44/65 (67.7%) patients with moderate or severe depression at baseline improved to a milder or no depression subgroup at week 52.

Shifts in BDI-II categories over 52 weeks were accompanied by decreases (improvements) in mean BDI-II scores from baseline in subgroups with baseline depression (Table II). Despite these improvements, patients with more severe depression at baseline continued to report higher mean BDI-II values at week 52 (mean [SD] of 27.0 [12.9] for patients with severe depression compared with 7.6 [7.2] for patients with no depression; Suppl. Table S3).
Effect of tocilizumab on depression in RA / F. Behrens et al.

Table III. Pearson correlation coefficients (r values) for change from baseline to week 52.

<table>
<thead>
<tr>
<th>Variable</th>
<th>BDI-II</th>
<th>Pain</th>
<th>Fatigue</th>
<th>Sleep difficulty</th>
<th>PGA</th>
<th>PhGA</th>
<th>STAI-State</th>
<th>STAI-Trait</th>
</tr>
</thead>
<tbody>
<tr>
<td>BDI-II</td>
<td>1.0 (NA)</td>
<td>0.36 (0.23–0.48)</td>
<td>0.27 (0.13–0.40)</td>
<td>0.31 (0.17–0.44)</td>
<td>0.28 (0.15–0.40)</td>
<td>0.13 (0.00–0.26)</td>
<td>0.44 (0.32–0.55)</td>
<td>0.53 (0.42–0.62)</td>
</tr>
<tr>
<td>DAS28-ESR</td>
<td>0.10 (-0.06–0.25)</td>
<td>0.45 (0.36–0.53)</td>
<td>0.30 (0.20–0.39)</td>
<td>0.29 (0.19–0.38)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>CDAI</td>
<td>0.05 (-0.08–0.18)</td>
<td>0.35 (0.27–0.42)</td>
<td>0.25 (0.17–0.33)</td>
<td>0.22 (0.14–0.30)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>

Variable data are presented as r values (95% CI).

BDI-II: Beck Depression Inventory II; CDAI: Clinical Disease Activity Index; CI: confidence interval; DAS28: Disease Activity Score based on 28 joint count; NA: not applicable; ND: not determined; PhGA: physician global assessment; PGA, patient global assessment.

We also evaluated the magnitude of changes in BDI-II scores over 52 weeks in patients with BDI-II data at baseline and week 52. About one-third of patients in the mild to severe depression subgroups had moderate to large improvements (decreases >10 points) in BDI-II scores and none experienced a moderate to large deterioration (increases >10 points) (Fig. 2).

Changes in additional outcomes over 52 weeks

Improvements in disease activity and PROs were observed in patients during the 52-week observation period (Table II; Suppl. Table S3). Patients with severe depression reported greater improvements in pain and fatigue than patients with no or milder depression (Table II).

Changes in disease activity were generally comparable among the different depression subgroups, but the frequency of individual therapeutic responses (DAS28-ESR-d_{52}) and remission rates decreased with more severe baseline depression. For instance, the DAS28-ESR-d_{52} response rate was 66.7% in the no depression subgroup compared with 51.7% in the severe depression subgroup, and CDAI remission rates were 32.9% and 13.2% for the no and severe depression subgroups, respectively.

Association between disease activity assessments, PROs, and BDI-II

At week 52, 166 patients had both DAS28-ESR and BDI-II data available. We analysed changes in BDI-II scores between baseline and week 52 in subgroups of these patients who did (n=99) or did not (n=67) achieve DAS28-ESR remission at week 52 (Fig. 3). The subgroup that did not achieve remission had approximately twice as many patients with a moderate to large deterioration in BDI-II subscores as the subgroup that achieved remission (12.0% vs. 6.1%), but patient numbers were small. In MMRM analyses (Suppl. Table S4), an association between DAS28-ESR and BDI-II was observed over time (p=0.016); higher values of DAS28-ESR (greater disease activity) corresponded to higher values of BDI-II (more severe depression). In contrast, BDI-II did not affect DAS28-ESR values over time (p=0.355).

In correlation analyses of change from baseline to week 52, BDI-II changes showed negligible correlations with changes in DAS28-ESR and CDAI (r=0.10 [95% CI -0.06–0.25] and 0.05 [95% CI -0.08–0.18], respectively; Table III), while changes in pain, fatigue, and sleep difficulty showed higher correlations with changes in disease activity measures (r=0.22 to 0.45; lower 95% CIs >0). Changes in BDI-II showed moderate correlations with PROs (pain, fatigue, sleep difficulty, STAI-State, STAI-Trait, and PGA), but not with PhGA (Table III). With the exception of PGA (r=0.28), BDI-II changes had minimal correlations with individual components of DAS28-ESR or CDAI (Suppl. Table S5 and Table III).

Safety evaluations

Patients with any severity of depression had more adverse events (125/226; 55.3%) than patients with no depression (102/248; 41.1%) and a higher frequency of serious adverse events (28/226 [12.4%] vs. 21/248 [8.5%]) (Table IV). However, the occurrence of adverse events did not correspond to severity of depression: the highest rate of serious adverse events was observed in patients with mild depression. In contrast, therapy discontinuation rates due to adverse events increased with higher levels of depression (from 11.3% in patients with no depression to 25.5% for moderate depression) and the proportion of patients with moderate or severe depression was greater in the subgroup with no depression to 25.5% for severe depression.

Table IV. Adverse events by baseline BDI-II subgroup.

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>No depression (BDI-II &lt;14) (n=248)</th>
<th>Mild depression (BDI-II 14-19) (n=87)</th>
<th>Moderate depression (BDI-II 20-28) (n=84)</th>
<th>Severe depression (BDI-II ≥29) (n=55)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AEs</td>
<td>102 (41.1%) [237]</td>
<td>48 (55.2%) [114]</td>
<td>47 (56.0%) [123]</td>
<td>30 (54.5%) [55]</td>
</tr>
<tr>
<td>SAEs</td>
<td>21 (8.5%) [41]</td>
<td>14 (16.1%) [19]</td>
<td>9 (10.7%) [9]</td>
<td>5 (9.1%) [8]</td>
</tr>
<tr>
<td>SAEs related to TCZ SC</td>
<td>7 (2.8%) [7]</td>
<td>5 (5.7%) [5]</td>
<td>3 (3.6%) [3]</td>
<td>0 (0.0%) [0]</td>
</tr>
<tr>
<td>Severe infections</td>
<td>4 (1.6%) [9]</td>
<td>1 (1.1%) [1]</td>
<td>0 (0.0%) [0]</td>
<td>1 (1.8%) [2]</td>
</tr>
<tr>
<td>AEs leading to therapy discontinuation</td>
<td>28 (11.3%) [36]</td>
<td>13 (14.9%) [14]</td>
<td>17 (20.2%) [21]</td>
<td>14 (25.5%) [15]</td>
</tr>
</tbody>
</table>

Data are presented as number of patients (%) [number of events].

AE: adverse event, BDI-II: Beck Depression Inventory II; SAE: serious adverse event; SC: subcutaneous; TCZ: tocilizumab.
Clinical and Experimental Rheumatology 2022

F. Behrens et al.

Effect of tocilizumab on depression in RA

severe depression) (Table IV). Adverse event rates were generally comparable in the BDI-II cohort compared with patients who did not complete the BDI-II (Suppl. Table S6).

Discussion

Depression is a common comorbidity in patients with RA and has the potential to influence outcomes and management. Patients with concomitant RA and depression have reduced quality of life (19), less improvement during biologic therapy (20), and a 35% higher mortality risk than RA patients without depression (21). The effects of depression extend to economic outcomes and health utilisation. RA patients with depression are more likely to apply for work disability; depression is a stronger predictor of early retirement for German patients with RA than age, functional disability, or disease activity (22). In a US study, concomitant depression was associated with more physician visits, emergency room visits, hospitalisations, and hospital days, resulting in an incremental adjusted annual cost of $8488 (23).

The association between RA and depression is not well understood and may be bidirectional. Depression can both cause and be exacerbated by increased inflammation (24). Although some studies have found that depression is associated with increased RA disease activity (19, 25), others have been unable to identify a direct association between disease activity and depressive symptoms after controlling for other factors (26-29). However, associations between depressive symptoms and PROs, including PGA and illness perceptions, have been consistently observed (26, 28, 29). Other influences, including personality type and socioeconomic factors, may also affect the impact of depressive symptoms in RA (27, 30).

Interpretation of studies of depression in RA is complicated by the fact that there are several different depression scales in use and some analyses combine patients with depression with those with anxiety (25, 26, 31, 32).

Minimal data are available concerning effective interventions for depression in RA. A recent meta-analysis identified only eight randomised trials of depression interventions in RA, and none had a high strength of evidence (33). Pharmacologic antidepressants appear to have some effect in reducing depressive symptoms in this patient population (33), but additional options are needed. Given the potential connection between inflammation and depression (4), the impact of anti-inflammatory therapies on depression has been the subject of much speculation. However, the anti-depressive effect of non-steroidal anti-inflammatory drugs remains unclear (34), while systemic glucocorticoids are associated with initial euphoria but can induce depressive symptoms during long-term use (35). In a recent study of 9000 patients treated with systemic or local (primarily inhaled/nasal) corticosteroids, regular corticosteroid use was associated with a 26% increase in risk of depressive symptoms or dysthymia (36).

Accordingly, anti-inflammatory effects do not appear to be sufficient for improvements in depression, although they may make some contribution. The possible utility of TNF inhibitors and other immunomodulators in treating depression is suggested by some studies (10, 37, 38). However, infliximab did not result in overall improvement in treatment-resistant depression in non-RA patients, although it was associated with improved depressive symptoms in the subgroup of patients with high baseline levels of inflammation (39), suggesting that effects on depression are mediated in part through anti-inflammatory activity. IL-6 is another potential target for anti-depressant therapies (38, 40), but a randomised study of sirukumab in major depressive disorder did not observe significant improvements in depressive symptoms in sirukumab-treated patients compared with placebo (41). Pilot studies to examine the effect of tocilizumab in patients with depression have been initiated (42, 43). Tocilizumab could potentially impact depressive symptoms through inhibition of IL-6, anti-inflammatory effects, as yet undetermined mechanisms of action, or a combination of some or all of these activities.

The objective of the current post-hoc analysis was to assess changes in symptoms of depression in tocilizumab-treated patients with RA during routine daily care. We found that depressive symptoms were common: almost half the patients (48%) who completed the BDI-II at baseline had some evidence of depression and 29% reported moderate or severe depression. The prevalence of depression documented here is higher than the 28% based on BDI-II scores in a recent cross-sectional study of RA patients in Germany (2). In both studies, the reported rate of depression during baseline comorbidity assessments was approximately 7.5%, suggesting that underdiagnosis and underrecognition of depression is widespread. Other studies have similarly noted underdiagnosis and undertreatment of depression in the RA patient population (44-46).

We found that baseline depression was associated with higher (poorer) PGA, HAQ-DI, fatigue, anxiety, and pain scores, but similar disease activity scores. This finding indicates that patients with similar disease activity levels can experience a wide range of levels of depression. PhGA scores were also similar across the depression subgroups. The discrepancy between PhGA and PROs suggests that depressive symptoms may have a different perception of their disease severity compared with the clinician’s assessment and objective measures of disease activity. Studies of discordance between PGA and PhGA have found that depressive symptoms are associated with worse patient ratings compared with physician ratings (47, 48).

Depressive symptoms improved substantially in the 52 weeks following initiation of tocilizumab therapy. Two-thirds of patients with moderate or severe depression improved to a milder depression or no depression subgroup, and about one-third showed moderate to large improvements (>10 points) in BDI-II scores. All of the subgroups showed improvements in disease activity, but response and remission rates varied markedly: patients with no or milder depression tended to achieve higher rates of response and remission than patients with severe depression, regardless of the assessment used to evaluate outcomes. Other studies have also observed lower remission rates in RA patients with depression or depression/anxiety (20, 25, 32, 49). These reduced response rates
Influence of biological therapy on depression in RA

Effect of tocilizumab on depression in RA / F. Behrens et al.

In clinical trials of anti-cytokine therapy, RA patients with moderate or mild depression had more adverse events than patients without depression. Improvements in depressive symptoms were also accompanied by improvements in PROs. Changes in pain corresponded closely to depression subgroups, with the greatest improvements observed in patients with severe depression and the least improvement in the no depression subgroup. This association mirrors baseline pain scores, which were higher in the severe depression subgroup. However, patterns of improvements in sleep disturbance, which also had the highest baseline levels in the severe depression subgroup, did not correspond to depression subgroups; the largest improvements were seen in patients with moderate or mild depression, despite previous findings that sleep quality is linked to pain and depression in patients with RA (50, 51). These varying patterns highlight the complex interplay among PROs. In analyses of the association between change in disease activity and depressive symptoms over time, we observed that whereas DAS28-ESR had a significant positive effect on BDI-II, BDI-II did not show an effect on DAS28-ESR. These analyses suggest that greater disease activity is associated with more severe depression, but depressive symptoms do not have a corresponding influence on disease activity. Correlation analyses found negligible correlations between changes from baseline in BDI-II and changes in disease activity measures, providing further support for a lack of association between depression symptoms and disease activity. BDI-II changes showed higher correlations with other PROs, particularly STAI anxiety, but not with PhGA, again suggesting that depressive symptoms have a greater influence on the patient’s perception of disease activity than on the physician’s assessment. Although these insights into possible associations between depression and disease activity are tantalising, it should be noted that this study was not designed to investigate these associations and our analyses should be considered exploratory. Patients with depression had more adverse events than patients without depression, and therapy discontinuation rates due to adverse events increased with severity of depression. Other therapeutic areas, ranging from diabetes (52) to epilepsy (53), have reported similar observations concerning the impact of depression on adverse event reports, but to the best of our knowledge this is the first report of this association in RA. Further studies will be required to evaluate whether this effect is related to underlying disease severity, physiologic changes related to depression, psychobehavioural characteristics, or some combination of these factors. Limitations of this study include challenges faced by all observational studies, including the lack of a comparator group. Although the subgroups were well-balanced with respect to age and disease activity, residual confounding is possible due to unidentified variables. Patient numbers were reduced because not all patients chose to complete the BDI-II questionnaire. Because patients were allowed to choose which PROs to complete, bias may potentially have been introduced by patient self-selection, although baseline characteristics of the two groups were comparable. Not all patients remained on tocilizumab for 52 weeks, but we believe it is unlikely that the small number who discontinued the study or stopped tocilizumab treatment significantly changed the results. In conclusion, our data document a high burden of depression in patients receiving routine clinical care for RA and clinically significant changes in symptoms of depression during the 52 weeks following initiation of tocilizumab therapy in tocilizumab-naïve patients with RA. Additional studies will be required to evaluate whether the impact of tocilizumab on depression is associated with or independent of improvement in disease activity, as well as to compare the effect of tocilizumab on depressive symptoms with other synthetic or biologic DMARDs used to treat RA. It will also be interesting to see if the potential association between tocilizumab and depressive symptoms is retained in treatment-naïve patients with RA. The effects of antirheumatic drugs on depression are highly relevant due to the increased prevalence and substantial burden of depression in patients with RA. We encourage rheumatologists and other clinicians who treat RA to consider the risk of depression during routine daily care and provide resources to assist in the management of depressive symptoms if appropriate.

Acknowledgements

The authors thank the patients, investigators, and nurses involved in the ARATA study. We thank Rainer Probst (AMS Advanced Medical Services GmbH, Munich, Germany) for statistical support and Prof. Harald Burkhardt (Goethe University, Frankfurt am Main, Germany) for critically reviewing the manuscript.

References

5. AL-HAKEIM HK, AL-RAMMAHI DA, AL-DUJAILI AH: IL-6, IL-18, sIL-2R, and TNF-a proinflammatory markers in depression and schizophrrenia patients who are free of overt inflammation. J Affect Disord 2015; 182: 106-14.
Effect of tocilizumab on depression in RA / F. Behrens et al.

als of chronic inflammatory conditions. Mol Psychiatry 2018; 23: 335-43.


14. JULIAN LJ: Measures of anxiety. State-Trait Anxiety Inventory (STAI), Beck Anxien


20. CALHOUF J, ALBRECHT K, SCHEFF G, ZINN A, WESTHOFF G: Depression is a stronger predictor of the risk to consider work disability in early arthritis than disease activity or response to therapy. RMD Open 2015; 1: e000020.


22. KIECOLT-GLASER J, DERRY HM, FAGUNDES CP: Inflammation: depression fans the flames and feasts on the heat. Am J Psychia


